First Eagle Investment Management LLC raised its stake in shares of Threshold Pharmaceuticals Inc. (NASDAQ:THLD) by 86.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,974,802 shares of the biotechnology company’s stock after buying an additional 2,775,369 shares during the period. First Eagle Investment Management LLC owned 8.36% of Threshold Pharmaceuticals worth $4,048,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of THLD. Oxford Asset Management increased its position in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the last quarter. Paloma Partners Management Co purchased a new position in Threshold Pharmaceuticals during the second quarter valued at $152,000. Finally, Deerfield Management Co. purchased a new position in Threshold Pharmaceuticals during the second quarter valued at $1,641,000. Institutional investors own 27.04% of the company’s stock.

Institutional Ownership by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)

Shares of Threshold Pharmaceuticals Inc. (NASDAQ:THLD) traded down 2.5253% on Wednesday, reaching $0.4825. The company’s stock had a trading volume of 842,489 shares. The company’s 50-day moving average is $0.44 and its 200 day moving average is $0.63. The company has a market capitalization of $34.53 million, a price-to-earnings ratio of 0.8015 and a beta of 4.78. Threshold Pharmaceuticals Inc. has a 12-month low of $0.21 and a 12-month high of $3.78.

Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. Equities analysts anticipate that Threshold Pharmaceuticals Inc. will post ($0.36) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this report can be accessed at

Several research firms have recently weighed in on THLD. S&P Equity Research cut their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a research note on Friday, September 30th. William Blair reiterated an “outperform” rating on shares of Threshold Pharmaceuticals in a research note on Monday, October 3rd.

Threshold Pharmaceuticals Company Profile

Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

5 Day Chart for NASDAQ:THLD

Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.